While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.
As 2019 nears its end, there are several major congresses remaining, not least the year’s biggest blood disorders meeting, the American Society of Hematology (ASH).
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
